The effect of resveratrol on the prevention of cisplatin ototoxicity

Basit Öğe Kaydı
dc.authoridBayindir, Tuba/0000-0003-4150-5016
dc.authorwosidBayindir, Tuba/ABG-9517-2020
dc.contributor.authorErdem, T.
dc.contributor.authorBayindir, Tuba
dc.contributor.authorFiliz, A.
dc.contributor.authorIraz, M.
dc.contributor.authorSelimoglu, E.
dc.date.accessioned2024-08-04T21:01:25Z
dc.date.available2024-08-04T21:01:25Z
dc.date.issued2012
dc.departmentİnönü Üniversitesien_US
dc.description.abstractOne of the most important adverse effects of cisplatin, a chemotherapeutic agent which is widely used in the treatment of cancer patients, is hearing loss. This has primarily been associated with the loss of inner ear hairy and spiral ganglion cells due to oxidative stress. Resveratrol is known to be an antioxidant agent, which has the theoretical potential of preventing cisplatin-related ototoxicity. This experimental study was approved by Animal Ethics Committee of Inonu University (2008-20) and supported by Inonu University Scientific Research Projects Support Fund (2009-17). Thirty-four 3-month-old Wistar albino female rats weighing 210-270 g were used in the study. The animals were allocated into four groups: in cisplatin group (Group A), a single dose of 12 mg/kg cisplatin was administered intraperitoneally to 10 rats; in cisplatin + resveratrol group (Group B), a single dose of 12 mg/kg cisplatin and 10 mg/kg resveratrol were administered intraperitoneally for 5 days to 10 rats; in resveratrol group (Group C), 10 mg/kg resveratrol was administered intraperitoneally for 5 days to seven rats and in control group (Group D), resveratrol solvent (5% alcohol-95% physiological saline) was administered intraperitoneally for 5 days to seven rats. Resveratrol administration has begun 1 day before cisplatin administration in the group treated with cisplatin and resveratrol combination. Distortion product otoacoustic emission (DPOAE) (Grason Stadler, Madison, USA) measurements were performed in the same ear of all rats (right ear) under general anesthesia at baseline, 1st and 5th days after drug administration. Statistically significant distortion product amplitude reductions were found in the cisplatin group at 1,418, 2,003, 3,363, 5,660, 8,003 and 9,515 Hz frequencies. Whereas in the cisplatin + resveratrol group, statistically significant difference was found between 1st and 5th day measurements only at 3,996 Hz frequency. No significant differences were noted between the measurements either in the resveratrol or in the control groups. According to these results, cisplatin-related ototoxicity has been greatly prevented by resveratrol use.en_US
dc.description.sponsorshipInonu University Scientific Research Project Units [2009-17]en_US
dc.description.sponsorshipThis study was funded by Inonu University Scientific Research Project Units (2009-17). This experiment was performed in proper with the guidelines of animal research which is setted by the National Institute of Health.en_US
dc.identifier.doi10.1007/s00405-011-1883-5
dc.identifier.endpage2188en_US
dc.identifier.issn0937-4477
dc.identifier.issue10en_US
dc.identifier.pmid22186767en_US
dc.identifier.startpage2185en_US
dc.identifier.urihttps://doi.org/10.1007/s00405-011-1883-5
dc.identifier.urihttps://hdl.handle.net/11616/104367
dc.identifier.volume269en_US
dc.identifier.wosWOS:000308241600005en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofEuropean Archives of Oto-Rhino-Laryngologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOtotoxicityen_US
dc.subjectCisplatinen_US
dc.subjectResveratrolen_US
dc.subjectAntioxidant agenten_US
dc.titleThe effect of resveratrol on the prevention of cisplatin ototoxicityen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu